Healx secures £7.7m Series A investment led by Balderton Capital to advance rare disease treatments
Balderton Capital led the Series A round with participation from Amadeus Capital Partners and Jonathan Milner.
Healx is a clinical-stage biotechnology company that uses artificial intelligence to discover and develop treatments for rare diseases. Based in Cambridge, the organisation combines advanced drug discovery techniques with a growing clinical pipeline.
Healx has secured £7.7m in a Series A funding round led by Balderton Capital. The investment also drew participation from existing backers including Jonathan Milner and Amadeus Capital Partners. The company applies artificial intelligence and pharmacological expertise to identify new uses for existing drugs, cutting development timelines for rare disease treatments.
Funds raised from the round will be used to expand the firm's multidisciplinary team of engineers, data scientists, and pharmacologists, as well as to further develop its machine learning technologies. The capital arrives as the company builds on successful collaborations with patient groups such as FRAXA for Fragile-X Syndrome.
From the founder
"Healx has a simple but profound goal: To transform the lives of rare disease patients. Our technology helps us find treatments where none currently exist,"
Tim Guilliams
CEO at Healx
Use of funds
- 01Grow the team
- 02Fund research and development
Investors
Categories
About the company
Healx
Healx deploys artificial intelligence to discover new therapies for rare conditions.